Multiple sclerosis (MS) is a condition that disrupts the information pathways that connect your brain and your body. From time to time, the symptoms of MS can unexpectedly worsen. When symptoms ...

The quest to understand and slow disease progression in multiple sclerosis (MS) continued in 2024, with research revealing possible new treatments and furthering knowledge about the disease course.

Prenatal and early life sun exposure was associated with lower risk for relapse in children with pediatric-onset multiple sclerosis (MS), a new prospective cohort study showed. At least 30 minutes of ...

Disability progression independent of relapse activity (PIRA) -- sometimes referred to as silent progression -- is a key integrating concept in the contemporary view of multiple sclerosis (MS). "The ...

Rituximab (Rituxan) provides consistently better relapse outcomes than natalizumab (Tysabri) in patients with multiple sclerosis (MS), new research suggests. Findings from a real-world "comparative ...

A blood test might predict when multiple sclerosis patients are about to suffer a relapse in their symptoms, a new study says. Blood levels of a protein called neurofilament light chain rise ...

Research shows that Blacks may develop multiple sclerosis more often than previously thought. Additionally, the symptoms of the disease can progress more quickly or have a higher severity. Still, ...

“Now, it means that we are not treating patients with therapies that should reduce and, in many cases, eliminate relapses,” she said, stressing that symptom change may not mean a relapse. “If a ...

Please provide your email address to receive an email when new articles are posted on . Research has shown that autologous hematopoietic stem cell transplantation is an effective treatment for MS. At ...

Christina Applegate is experiencing a "pretty bad" relapse of her multiple sclerosis , which she detailed on her new podcast with fellow MS sufferer Jamie-Lynn Sigler, MeSsy. Applegate, who was ...

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI ® (ublituximab-xiiy), to be presented (ACTRIMS) annual forum, being held February 5 – ...